Search in:

Advanced search

Vascular Health and Risk Management Volume 10, 2014 - Issue

Submit an article Journal homepage

Open access

124

Views

CrossRef citations to date

Altmetric

Letter

Perindopril for improving cardiovascular events

James J DiNicolantonioDepartment of Preventive Cardiology, Saint Luke’s Mid America Heart Institute, Kansas City, MO, USACorrespondence[email protected]

James H O’KeefeDepartment of Preventive Cardiology, Saint Luke’s Mid America Heart Institute, Kansas City, MO, USA

Pages 539-548 | Published online: 30 Aug 2014

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

WangJGPimentaEChwallekFComparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindoprilVasc Health Risk Manag20141018920024741317
PubMedGoogle Scholar
FoxKMEURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease InvestigatorsEfficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)Lancet2003362938678278813678872
PubMed Web of Science ®Google Scholar
FerrariRFoxKInsight into the mode of action of ACE inhibition in coronary artery disease: the ultimate ‘EUROPA’ storyDrugs200969326527719275271
PubMed Web of Science ®Google Scholar
DiNicolantonioJJLavieCJO’KeefeJHNot All Angiotensin-Converting Enzyme Inhibitors Are Equal: Focus on Ramipril and PerindoprilPostgrad Med2013125415416823933903
PubMed Web of Science ®Google Scholar
AseevaOACoversyl: At the core of cardiovascular disease prevention and treatmentMedicographia20093116976
Google Scholar
RemmeWJDeckersJWFoxKMFerrariRBertrandMSimoonsMLEUROPA InvestigatorsSecondary prevention of coronary disease with ACE inhibition – does blood pressure reduction with perindopril explain the benefits in EUROPA?Cardiovasc Drugs Ther200923216117018931896
PubMed Web of Science ®Google Scholar
CeconiCFoxKMRemmeWJACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENTCardiovasc Res200773123724617140552
PubMed Web of Science ®Google Scholar
ManciaGParatiGBiloGAmbulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)Hypertension20126061400140623071122
PubMed Web of Science ®Google Scholar
PoulterNRWedelHDahlöfBRole of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)Lancet2005366948990791316154017
PubMed Web of Science ®Google Scholar
WilliamsBLacourcièreYSchumacherHGossePNeutelJMAntihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trialsJ Hum Hypertens200923961061919225530
PubMed Web of Science ®Google Scholar
YusufSSleightPPogueJBoschJDaviesRDagenaisGEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med2000342314515310639539
PubMed Web of Science ®Google Scholar
[No authors listed]Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study InvestigatorsLancet199334288758218288104270
PubMed Web of Science ®Google Scholar
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) InvestigatorsYusufSTeoKEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet200837296441174118318757085
PubMed Web of Science ®Google Scholar
YusufSDienerHCSaccoRLTelmisartan to prevent recurrent stroke and cardiovascular eventsN Engl J Med2008359121225123718753639
PubMed Web of Science ®Google Scholar
WangWMaLYLiuMBEffects of amlodipine plus telmisartan or amlodipine plus amiloride regimen on blood pressure control in hypertensive patients: preliminary report of Chinese Hypertension Intervention Efficacy (CHIEF) trial. ESH congress, oral presentation, Milan 2013Cardiotimes2013 Available from: http://www.cardiotimes.com/?s=chiefAccessed July 31, 2014
Google Scholar
TropeanoAIBoutouyriePPannierBBrachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensivesHypertension2006481808616702490
PubMed Web of Science ®Google Scholar
Blood Pressure Lowering Treatment Trialists’ CollaborationTurnbullFNealBPfefferMBlood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin systemJ Hypertens200725595195817414657
PubMed Web of Science ®Google Scholar
TurnbullFBlood Pressure Lowering Treatment Trialists’ CollaborationEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet200336293951527153514615107
PubMed Web of Science ®Google Scholar
BarnettAHBainSCBouterPAngiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathyN Engl J Med2004351191952196115516696
PubMed Web of Science ®Google Scholar
NissenSETuzcuEMLibbyPEffect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trialJAMA2004292182217222515536108
PubMed Web of Science ®Google Scholar
ONTARGET InvestigatorsYusufSTeoKKTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
PubMed Web of Science ®Google Scholar
MannJFSchmiederREMcQueenMRenal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trialLancet2008372963854755318707986
PubMed Web of Science ®Google Scholar
StraussMHHallASAngiotensin Receptor Blockers May Increase Risk of Myocardial Infarction Unraveling the ARB-MI ParadoxCirculation2006114883885416923768
PubMed Web of Science ®Google Scholar
van VarkLCBertrandMAkkerhuisKMAngiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patientsEur Heart J201233162088209722511654
PubMed Web of Science ®Google Scholar
ChengJZhangWZhangXEffect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysisJAMA Intern Med2014174577378524687000
PubMed Web of Science ®Google Scholar
WuHYHuangJWLinHJComparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysisBMJ2013347f600824157497
PubMed Web of Science ®Google Scholar
SavareseGCostanzoPClelandJGA meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failureJ Am Coll Cardiol201361213114223219304
PubMed Web of Science ®Google Scholar
RemkováAKratochvíl’ováHDurinaJImpact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertensionJ Hum Hypertens200822533834518305548
PubMed Web of Science ®Google Scholar
GhiadoniLMagagnaAVersariDDifferent effect of antihypertensive drugs on conduit artery endothelial functionHypertension20034161281128612719441
PubMed Web of Science ®Google Scholar
FerrariRPerindopril and Remodeling in Elderly with Acute Myocardial Infarction InvestigatorsEffects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) StudyArch Intern Med2006166665966616567606
PubMedGoogle Scholar
PROGRESS Collaborative GroupRandomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attackLancet20013581033104111589932
PubMed Web of Science ®Google Scholar
Tumanan-MendozaBADansALVillacinLLDechallenge and rechallenge method showed different incidences of cough among four ACE-IsJ Clinic Epidemiol2007606547553
PubMed Web of Science ®Google Scholar
YesilSYesilMBayataSPostaciNACE inhibitors and coughAngiology19944598058088092546
PubMed Web of Science ®Google Scholar
VítovecJSpinarJFirst-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril. Slovak Investigator GroupEur J Heart Fail20002329930410938492
PubMed Web of Science ®Google Scholar
ReidJLMacFadyenRJSquireIBLeesKRBlood pressure response to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failureAm J Cardiol1993711757E60E7678367
PubMed Web of Science ®Google Scholar
LauCPTseHFNgWComparison of perindopril versus captopril for treatment of acute myocardial infarctionAm J Cardiol200289215015411792333
PubMed Web of Science ®Google Scholar
NedogodaSVLedyaevaAAChumachokEVRandomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertensionClin Drug Investig2013338553561
PubMed Web of Science ®Google Scholar
RomanMJDevereuxRBKizerJRCentral pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart StudyHypertension200750119720317485598
PubMed Web of Science ®Google Scholar
VerdecchiaPPrognostic value of ambulatory blood pressure: current evidence and clinical implicationsHypertension200035384485110720605
PubMed Web of Science ®Google Scholar
MakaniHBangaloreSSupariwalaARomeroJArgulianEMesserliFHAntihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysisEur Heart J201435261732174223966312
PubMed Web of Science ®Google Scholar
PatelAADVANCE Collaborative GroupMacMahonSEffects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialLancet2007370959082984017765963
PubMed Web of Science ®Google Scholar

References

MatcharDBMcCroryDCOrlandoLASystematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertensionAnn Intern Med20081481162917984484
PubMed Web of Science ®Google Scholar
ManciaGFagardRNarkiewiczK2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens20133171281135723817082
PubMed Web of Science ®Google Scholar
National Institute for Health and Care Excellence [homepage on the Internet]Hypertension: Clinical management of primary hypertension in adults2011 Available from: http://www.nice.org.uk/guidance/CG127/chapter/IntroductionAccessed July 25, 2014
Google Scholar
López-JaramilloPSánchezRADiazMLatin American consensus on hypertension in patients with diabetes type 2 and metabolic syndromeJ Hypertens201331222323823282894
PubMed Web of Science ®Google Scholar
MichelMCFosterCBrunnerHRLiuLA systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonistsPharmacol Rev201365280984823487168
PubMed Web of Science ®Google Scholar
RagotSEzzaherAMeunierAPoterreMBourkaibRHerpinDComparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE studyJ Hum Hypertens2002161286587312522468
PubMed Web of Science ®Google Scholar
Heads of Medicine Agencies [homepage on the Internet]Coveram^® (perindopril arginine/amlodipine besylate) SPC Available from: http://mri.medagencies.org/Human/Product/Details/10968Accessed July 25, 2014
Google Scholar
CostaFVDegli EspostiLCerraCVeronesiCBudaSTrends in prescription and determinants of persistence to antihypertensive therapy: the PAPEETE studyHigh Blood Press Cardiovasc Prev200916416717623334908
PubMedGoogle Scholar
BangaloreSKumarSMesserliFHAngiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians’ Desk ReferenceAm J Med2010123111016103021035591
PubMed Web of Science ®Google Scholar
ReboldiGAngeliFCavalliniCGentileGManciaGVerdecchiaPComparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysisJ Hypertens20082671282128918550998
PubMed Web of Science ®Google Scholar
McAlisterFARenin Angiotensin System Modulator Meta-Analysis InvestigatorsAngiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trialsEur Heart J201233450551422041554
PubMed Web of Science ®Google Scholar
GersteinHCMannJFYiQAlbuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individualsJAMA2001286442142611466120
PubMed Web of Science ®Google Scholar
FoxKMEURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease InvestigatorsEfficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)Lancet2003362938678278813678872
PubMed Web of Science ®Google Scholar
LewingtonSClarkeRQizilbashNPetoRCollinsRProspective Studies CollaborationAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet200236093491903191312493255
PubMed Web of Science ®Google Scholar
JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436394262022203115207952
PubMed Web of Science ®Google Scholar
PROGRESS Collaborative GroupRandomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attackLancet200135892871033104111589932
PubMed Web of Science ®Google Scholar
Erratum in:Lancet200235993232120
Google Scholar
Lancet200135892921556
Google Scholar
DahlöfBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet2005366948989590616154016
PubMed Web of Science ®Google Scholar
YusufSSleightPPogueJEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med2000342314515310639539
PubMed Web of Science ®Google Scholar
Erratum in:N Engl J Med2000342107482000342181376
Web of Science ®Google Scholar
GommaAHFoxKMThe EUROPA trial: design, baseline demography and status of the substudiesCardiovasc Drugs Ther200115216917911669411
PubMed Web of Science ®Google Scholar
ONTARGET InvestigatorsYusufSTeoKKTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
PubMed Web of Science ®Google Scholar
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) InvestigatorsYusufSTeoKEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet200837296441174118318757085
PubMed Web of Science ®Google Scholar
YusufSDienerHCSaccoRLTelmisartan to prevent recurrent stroke and cardiovascular eventsN Engl J Med2008359121225123718753639
PubMed Web of Science ®Google Scholar
US Food and Drug Administration [homepage on the Internet]US Department of Health and Human ServicesCenter for Drug Evaluation and Research (CDER)Guidance for industry: hypertension indication: drug labeling for cardiovascular outcome claims2011 Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm075072.pdfAccessed July 25, 2014
Google Scholar
SeverPSThe Anglo-Scandinavian Cardiac Outcomes Trial: implications and further outcomesHypertension201260224825922753211
PubMed Web of Science ®Google Scholar
NealBMacMahonSChapmanNBlood Pressure Lowering Treatment Trialists’ CollaborationEffects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trialsLancet200035692461955196411130523
PubMed Web of Science ®Google Scholar
TurnbullFBlood Pressure Lowering Treatment Trialists’ CollaborationEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet200336293951527153514615107
PubMed Web of Science ®Google Scholar
European Medicines Agency [homepage on the Internet]Assessment report for Micardis (telmisartan)European Medicines Agency2009 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000209/WC500073444.pdfAccessed July 25, 2014
Google Scholar
European Medicines Agency [homepage on the Internet]Committee for Medicinal Products for Human Use opinion following an Article 6 (12) referral: perindopril2005 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Coversyl/human_referral_000138.jsp&mid=WC0b01ac05805c516fAccessed July 25, 2014
Google Scholar
BarnettAHBainSCBouterPAngiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathyN Engl J Med2004351191952196115516696
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Perindopril for improving cardiovascular events

References

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Perindopril for improving cardiovascular events

References

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date